Cas No.: | 71827-03-7 |
Chemical Name: | Ivermectin B1a |
SMILES: | C/C([C@H]([C@H](/C=C/C=C1CO[C@]([H])([C@@H](C(C)=C[C@]2(C3=O)[H])O)[C@@]\12O)C)O[C@]4(C[C@@H]([C@H]([C@@H](O4)C)O[C@@]5(O[C@H]([C@@H]([C@H](C5)OC)O)C)[H])OC)[H])=C\C[C@@]6(C[C@@]([H])(C[C@@]7(O6)CC[C@@H]([C@]([H])(O7)[C@@H](C)CC)C)O3)[H] |
Formula: | C48H74O14 |
M.Wt: | 875.09 |
Purity: | >98% |
Sotrage: | Powder-20°C3 yearsIn solvent-80°C6 months-20°C1 month |
Description: | Ivermectin B1a, a derivative of Avermectin B1a, is a main component of Ivermectin. Ivermectin (MK-933) is a broad-spectrum anti-parasite agent. Ivermectin is a candidate therapeutic against SARS-CoV-2/COVID-19. |
In Vitro: | Ivermectin belongs to the macrocyclic lactone class of avermectins and consists of a mixture of two homologous compounds, ivermectin B1a (not less than 80%) and ivermectin B1b (not more than 20%). Ivermectin B1a, the major component of Ivermectin, is inactive at a concentration of 0.3 μg/ml, whereas in the case of the minor component, ivermectin B1b, the same concentration produces 100% mortality of snails[1]. |
References: | [1]. Naftale Kat, et al. Ivermectin Efficacy Against Biomphalaria, Intermediate Host Snail Vectors of Schistosomiasis. J Antibiot (Tokyo). 2017 May;70(5):680-684. [2]. Khan Sharun, et al. Ivermectin, a New Candidate Therapeutic Against SARS-CoV-2/COVID-19. Ann Clin Microbiol Antimicrob. 2020 May 30;19(1):23. |